Company news

CorMedix Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

October 22, 2024

CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator

October 7, 2024

CorMedix Inc. Announces New Commercial Agreement

September 18, 2024

CorMedix Inc. to Present at the Cantor Global Healthcare Conference

September 12, 2024

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

August 13, 2024

CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

August 6, 2024

CorMedix Inc. Announces Outpatient Availability of DefenCath

July 2, 2024

CorMedix Inc. Receives FDA Feedback on Potential Label Expansion

June 17, 2024

CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

June 5, 2024

CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

May 27, 2024

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

May 9, 2024

CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

May 5, 2024

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

April 18, 2024

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

April 14, 2024

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

April 10, 2024

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

April 7, 2024

CorMedix Inc. to Present at the Needham Annual Healthcare Conference

March 26, 2024

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 11, 2024

CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024

March 5, 2024

CorMedix Inc. Announces Commercial and Reimbursement Updates

January 29, 2024

CorMedix Inc. Announces Commercial and Operational Updates

January 7, 2024

CorMedix Inc. Announces Appointment of Chief Legal Officer

December 14, 2023

CorMedix Inc. Announces Partnership With The Leapfrog Group

December 3, 2023

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

November 14, 2023

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

November 13, 2023

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

November 1, 2023

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

October 10, 2023

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

September 25, 2023

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

September 7, 2023

CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

September 5, 2023

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath

August 29, 2023

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

August 7, 2023

CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023

July 25, 2023

CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 27, 2023

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

June 27, 2023

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

June 20, 2023

Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections

June 14, 2023

Cormedix Inc. To Present At The Jefferies Healthcare Conference

May 29, 2023

CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath

May 15, 2023

CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 14, 2023

CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023

May 7, 2023

CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

April 30, 2023

CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates

April 25, 2023

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

April 16, 2023

CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 29, 2023

Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023

March 20, 2023

CorMedix Inc. Announces Regulatory and Manufacturing Updates

March 1, 2023

CorMedix Inc. Announces Promotions in Commercial and Tech Ops

January 16, 2023

Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections

December 5, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.